Ken A Brameld

Years Active: 2017-2022
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Timothy D Owens, Ken A Brameld, Erik J Verner, Tony Ton, Xiaoyan Li, Jiang Zhu, Mohammad R Masjedizadeh, J Michael Bradshaw, Ronald J Hill, Danny Tam, Angelina Bisconte, Eun Ok Kim, Michelle Francesco, Yan Xing, Jin Shu, Dane Karr, Jacob LaStant, David Finkle, Natalie Loewenstein, Helena Haberstock-Debic, Michael J Taylor, Philip Nunn, Claire L Langrish, David M Goldstein
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib). Journal of medicinal chemistry 65 (7) (2022)
Claire L Langrish, J Michael Bradshaw, Michelle R Francesco, Timothy D Owens, Yan Xing, Jin Shu, Jacob LaStant, Angelina Bisconte, Catherine A Outerbridge, Stephen D White, Ronald J Hill, Ken A Brameld, David M Goldstein, Philip A Nunn
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. Journal of immunology (Baltimore, Md. : 1950) 206 (7) (2021)
Ken A Brameld, Timothy D Owens, Erik Verner, Eleni Venetsanakos, J Michael Bradshaw, Vernon T Phan, Danny Tam, Kwan Leung, Jin Shu, Jacob LaStant, David G Loughhead, Tony Ton, Dane E Karr, Mary E Gerritsen, David M Goldstein, Jens Oliver Funk
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. Journal of medicinal chemistry 60 (15) (2017)

Ken A Brameld.css-eqlu8i{font-size:small;padding-left:4px;}